Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026

Same author

Timing Is Not Everything: Reassessing Chrono-Immunotherapy in Clinical Practice.

JCO oncology practice·2026

Same author

Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.

Journal for immunotherapy of cancer·2026

Same author

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.

Cancer research communications·2025

Same author

IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma.

Journal for immunotherapy of cancer·2025

Search research articles

Related Experiment Video

Updated: Aug 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Myeloid Maturity: ATRA to Enhance Anti-PD-1?

Daniel J Olson¹, Jason J Luke²

¹University of Chicago Comprehensive Cancer Center, Chicago, Illinois.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|January 19, 2023

Summary

This summary is machine-generated.

Myeloid-derived suppressor cells (MDSC) can cause resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may overcome this by maturing MDSCs, potentially enhancing immunotherapy effectiveness when combined with pembrolizumab.

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Aug 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Area of Science:

Immunology
Cancer Therapy
Pharmacology

Background:

Myeloid-derived suppressor cells (MDSC) are implicated in resistance to immune checkpoint inhibitors, particularly anti-PD-1 therapies.
Understanding the mechanisms of MDSC-mediated immunosuppression is crucial for improving cancer treatment outcomes.

Discussion:

All-trans retinoic acid (ATRA) has been shown to induce MDSC maturation, potentially reversing their suppressive functions.
Combining ATRA with pembrolizumab (an anti-PD-1 antibody) presents a strategy to target MDSC-mediated resistance.

Key Insights:

MDSC are a significant barrier to successful anti-PD-1 therapy.
ATRA can modulate MDSC, offering a potential therapeutic avenue.
Combination therapy of ATRA and pembrolizumab may enhance anti-tumor immunity.

Outlook:

Further clinical investigation is warranted to validate the efficacy of ATRA in combination with pembrolizumab for various cancers.
This approach could represent a novel strategy to improve outcomes for patients resistant to current immunotherapies.